The effect of insulin and glucose on the plasma concentration of Alzheimer's amyloid precursor protein

Neuroscience

Volumn 95, Issue 3, 1999, Pages 727-734

  Boyt, A A ^b   Taddei, K ^b   Hallmayer, J ^b   Helmerhorst, E ^c   Gandy, S E ^d   Craft, S ^e   Martins, R N ^a,b  

^a Hollywood Priv Hosp Monash Avenue   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c CURTIN UNIVERSITY   (Australia)

^d NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Alzheimer's; Amyloid; Apolipoprotein E; Diabetes; Glucose; Insulin

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; GLUCOSE; INSULIN; MONOCLONAL ANTIBODY;

ADULT; ALZHEIMER DISEASE; ANTIGEN ANTIBODY REACTION; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; INSULIN BLOOD LEVEL; MEMORY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN METABOLISM; PROTEIN PURIFICATION;

ADMINISTRATION, ORAL; ADULT; ALLELES; AMYLOID BETA-PROTEIN PRECURSOR; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BLOOD GLUCOSE; GLUCOSE; HUMANS; INSULIN; MIDDLE AGED; OSMOLAR CONCENTRATION; REFERENCE VALUES;

EID: 0032794486     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(99)00458-3     Document Type: Article

References (77)

1. Barger S.W., Mattson M.P. Isoform-specific modulation by apolipoprotein E of the activities of secreted ß-amyloid precursor protein. J. Neurochem. 69:1997;60-67.
2. Behl C., Davis J.B., Klier F.G., Schubert D. Amyloid beta peptide induces necrosis rather than apoptosis. Brain Res. 645:1994;253-264.
3. Behl C., Davis J.B., Lesley R., Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell. 77:1994;817-827.
4. Bush A.I., Martins R.N., Rumble B., Moir R., Fuller S., Milward E., Currie J., Ames D., Weidemann A., Fischer P., Multhaup G., Beyreuther K., Masters C.L. The amyloid precursor protein of Alzheimer's disease is released by human platelets. J. biol. Chem. 265:1990;15,977-15,983.
5. Bush A.I., Whyte S., Thomas L.D., Williamson T.G., Van Tiggelen C.J., Currie J., Small D.H., Moir R.D., Li Q., Rumble B., Manning U., Beyreuther K., Masters C. L. An abnormality of plasma amyloid protein precursor in Alzheimer's disease. Ann. Neurol. 32:1992;57-65.
6. Bush A.I., Multhaup G., Moir R.D., Williamson T.G., Small D.H., Rumble B., Pollwein P., Beyreuther K., Masters C.L. A novel zinc(II) binding site modulates the function of the beta A4 amyloid protein precursor of Alzheimer's disease. J. biol. Chem. 268:1993;16,109-16,112.
7. Chen M., Inestrosa N.C., Ross G.S., Fernandez H.L. Platelets are the primary source of amyloid ß-peptide in human blood. Biochem. biophys. Res. Commun. 213:1995;96-103.
8. Craft S., Zallen G., Baker L.D. Glucose and memory in mild senile dementia of the Alzheimer type. J. clin. exp. Neuropsychol. 14:1992;253-267.
9. Craft S., Dagogo-Jack S.E., Wiethop B.V., Murphy C., Nevins R.T., Fleischman S., Rice V., Newcomer J.W., Cryer P.E. Effects of hyperglycemia on memory and hormone levels in dementia of the Alzheimer type: a longitudinal study. Behav. Neurosci. 107:1993;926-940.
10. Craft S., Newcomer J., Kanne S., Dagogo-Jack S., Cryer P., Sheline Y., Luby J., Dagogo-Jack A., Alderson A. Memory improvement following induced hyperinsulinemia in Alzheimer's disease. Neurobiol. Aging. 17:1996;123-130.
11. Craft S., Peskind E., Schwartz M.W., Schellenberg G.D., Raskind M., Porte D. Jr. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology. 50:1998;164-168.
12. Descamps O., Bilheimer D., Herz J. Insulin stimulates receptor-mediated uptake of apoE-enriched lipoproteins and activated alpha 2-macroglobulin in adipocytes. J. biol. Chem. 268:1993;974-981.
13. Duara R., Grady C., Haxby J., Sundaram M., Cutler N.R., Heston L., Moore A., Schlageter N., Larson S., Rapoport S.I. Positron emission tomography in Alzheimer's disease. Neurology. 36:1986;879-887.
14. 18F]fluorodeoxyglucose. J. Comput. assist. Tomogr. 7:1983;590-598.
15. Friedland R.P., Jagust W.J., Huesman R.H., Koss E., Knittel B., Mathis C.A., Ober B.A., Mazoyer B.M., Budinger T.F. Regional cerebral glucose transport and utilization in Alzheimer's disease. Neurology. 39:1989;1427-1434.
16. Gasparini L., Racchi M., Benussi L., Curti D., Binetti G., Bianchetti A., Trabucchi M., Govoni S. Effect of energy shortage and oxidative stress on amyloid precursor protein metabolism in COS cells. Neurosci. Lett. 231:1997;113-117.
17. Ha S., Fresser F., Köchl S., Beyreuther K., Utermann G., Baier G. Physical interaction of ApoE with amyloid precursor protein independent of the amyloid Aβ region in vitro. J. biol. Chem. 273:1998;13,892-13,897.
18. Haas C., Cazorla P., De Miguel C., Valdivieso F., Vázquez J. Apolipoprotein E forms stable complexes with recombinant Azheimer's disease ß-amyloid precursor protein. Biochem. J. 325:1997;169-175.
19. Haxby J.V., Grady C.L., Koss E., Horwitz B., Schapiro M., Friedland R.P., Rapoport S.I. Heterogeneous anterior-posterior metabolic patterns in dementia of the Alzheimer type. Neurology. 38:1988;1853-1863.
20. Hensley K., Carney J.M., Mattson M.P., Aksenova M., Harris M., Wu J.F., Floyd R.A., Butterfield D.A. A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc. natn. Acad. Sci. U.S.A. 91:1994;3270-3274.
21. Hixson J.E., Vernier D.T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J. Lipid Res. 31:1990;545-548.
22. Ho L., Fukuchi K., Younkin S.G. The alternatively spliced Kunitz protease inhibitor domain alters amyloid beta protein precursor processing and amyloid beta protein production in cultured cells. J. biol. Chem. 271:1996;30,929-30,934.
23. Ibanez V., Pietrini P., Alexander G.E., Furey M. L, Teichberg D., Rajapakse J.C., Rapoport S.I., Schapiro M.B., Horwitz B. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology. 50:1998;1585-1593.
24. Ishii K., Sasaki M., Kitagaki H., Yamaji S., Sakamoto S., Matsuda K., Mori E. Reduction of cerebellar glucose metabolism in advanced Alzheimer's disease. J. Nucl. Med. 38:1997;925-928.
25. Ko L., Sheu K.R., Blass J.P. Immunohistochemical colocalization of amyloid precursor protein with cerebrovascular amyloid of Alzheimer's disease. Am. J. Pathol. 139:1991;523-533.
26. Kounnas M.Z., Moir R.D., Rebeck G.W., Bush A.I., Argraves W.S., Tanzi R.E., Hyman B.T., Strickland D.K. LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted ß-amyloid precursor protein and mediates its degradation. Cell. 82:1995;331-340.
27. Kurochkin I.V., Goto S. Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insuin degrading enzyme. Fedn Eur. biochem. Socs Lett. 345:1994;33-37.
28. Landi F., Bernabei R., Gambassi G. Non-insulin-dependent diabetes mellitus and Alzheimer's disease. J. Am. geriatr. Soc. 45:1997;654-655.
29. Laskowski M. Jr., Kato I. Protein inhibitors of proteinases. A. Rev. Biochem. 49:1980;593-626.
30. Leibson C.L., Rocca W.A., Hanson V.A., Cha R., Kokmen E., O'Brien P.C., Palumbo P.J. The risk of dementia among persons with diabetes mellitus: a population-based cohort study. Ann. N.Y. Acad. Sci. 826:1997;422-427.
31. Li Q., Evin G., Small D., Multhaup G., Beyreuther K., Masters C.L. Proteolytic processing of Alzheimer's disease ßA4 amyloid precursor protein in human platelets. J. biol. Chem. 270:1995;14,140-14,147.
32. Martins R.N., Robinson P.J., Chleboun J.O., Beyreuther K., Masters C.L. The molecular pathology of amyloid deposition in Alzheimer's disease. Molec. Neurobiol. 5:1991;389-398.
33. Martins R. N., Turner B., Muir J., Brooks B., Creasey H. and Broe A. (1993) The circulating forms of the amyloid precursor protein in Alzheimer's disease; XVth Congress Internat. Assoc. Gerontol. pp. 559-563.
34. Martins R.N., Muir J., Brooks W.S., Creasy H., Montgomery P., Sellers P., Broe G.A. Plasma amyloid precursor protein is decreased in Alzheimer's disease. NeuroReport. 4:1993;757-759.
35. Martins R.N., Clarnette R., Fisher C., Broe G.A., Brooks W.S., Montgomery P., Gandy S.E. ApoE genotypes in Australia: roles in early and late onset Alzheimer's disease and Down's syndrome. NeuroReport. 6:1995;1513-1516.
36. Masters C.L., Multhaup G., Simms G., Pottgiesser J., Martins R.N., Beyreuther K. Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. Eur. molec. Biol. Org. J. 4:1985;2757-2763.
37. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. natn. Acad. Sci. U.S.A. 82:1985;4245-4249.
38. McDermott J.R., Gibson A.M. Degradation of Alzheimer's beta-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme. Neurochem. Res. 22:1997;49-56.
39. Meier-Ruge W.A., Bertoni-Freddari C. Pathogenesis of decreased glucose turnover and oxidative phosphorylation in ischemic and trauma-induced dementia of the Alzheimer type. Ann. N.Y. Acad. Sci. 26:1996;229-241.
40. Meneilly G.S., Hill A. Alterations in glucose metabolism in patients with Alzheimer's disease. J. Am. geriatr. Soc. 41:1993;710-714.
41. Messier C., Gagnon M. Glucose regulation and cognitive functions: relation to Alzheimer's disease and diabetes. Behav. Brain Res. 75:1996;1-11.
42. Meyer M., Koeppe R.A., Frey K.A., Foster N.L., Kuhl D.E. Positron emission tomography measures of benzodiazepine binding in Alzheimer's disease. Archs Neurol. 52:1995;314-317.
43. Mielke R., Herholz K., Grond M., Kessler J., Heiss W.D. Clinical deterioration in probable Alzheimer's disease correlates with progressive metabolic impairment of association areas. Dementia. 5:1994;36-41.
44. Mielke R., Schroder R., Fink G.R., Kessler J., Herholz K., Heiss W.D. Regional cerebral glucose metabolism and postmortem pathology in Alzheimer's disease. Acta neuropath. 91:1996;174-179.
45. Moir R.D., Martins R.N., Bush A.I., Small D.H., Milward E.A., Rumble B.A., Multhaup G., Beyreuther K., Masters C.L. Human brain ßA4 amyloid protein precursor of Alzheimer's disease: purification and partial characterization. J. Neurochem. 59:1992;1490-1498.
46. Moir R.D., Lynch T., Bush A.I., Whyte S., Henry A., Portbury S., Multhaup G., Small D.H., Tanzi R.E., Beyreuther K. Relative increase in Alzheimer's disease of soluble forms of cerebral Abeta amyloid protein precursor containing the Kunitz protease inhibitory domain. J. biol. Chem. 273:1998;5013-5019.
47. Murphy M. The molecular pathogenesis of Alzheimer's disease: clinical prospects. Lancet. 340:1992;1512-1515.
48. Narindrasorasak S., Lowery D., Gonzalez-DeWhitt P., Poorman R.A., Greenberg B., Kisilevsky R. High affinity interactions between the Alzheimer's beta-amyloid precursor proteins and the basement membrane form of heparan sulfate proteoglycan. J. biol. Chem. 266:1991;12,878-12,883.
49. Narita M., Holtzman D.M., Schwartz A.L., Bu G.J. Alpha(2)-macroglobulin complexes with and mediates the endocytosis of beta-amyloid peptide via cell surface low-density lipoprotein receptor-related protein. J. Neurochem. 69:1997;1904-1911.
50. Nomura S., Komiyama Y., Miyake T., Miyazaki Y., Kido H., Suzuki M., Kagawa H., Yanabu M., Takahashi H., Fukuhara S. Amyloid beta-protein precursor-rich platelet microparticles in thrombotic disease. Thromb. Haemost. 72:1994;519-522.
51. Olesen O.F., Mikkelsen J.D., Gerdes C., Jensen P.H. Isoform-specific binding of human apolipoprotein E to the non-amyloid beta component of Alzheimer's disease amyloid. Molec. Brain Res. 44:1997;105-112.
52. Ott A., Stolk R.P., Hofman A., van Harskamp F., Grobbee D.E., Breteler M.M. Association of diabetes mellitus and dementia: the Rotterdam study. Diabetologia. 39:1996;1392-1397.
53. Palmert M.R., Podlisny M.B., Witker D.S., Oltersdorf T., Younkin L.H., Selkoe D.J., Younkin S.G. Antisera to an amino-terminal peptide detect the amyloid protein precursor of Alzheimer's disease and recognize senile plaques. Biochem. biophys. Res. Commun. 156:1988;432-437.
54. Palmert M.R., Siedlak S.L., Podlisny M.B., Greenberg B., Shelton E.R., Chan H.W., Usiak M., Selkoe D.J., Perry G., Younkin S.G. Soluble derivatives of the beta amyloid protein precursor of Alzheimer's disease are labeled by antisera to the beta amyloid protein. Biochem. biophys. Res. Commun. 165:1989;182-188.
55. Palmert M.R., Podlisny M.B., Witker D.S., Oltersdorf T., Younkin L.H., Selkoe D.J., Younkin S.G. The beta-amyloid protein precursor of Alzheimer disease has soluble derivatives found in human brain and cerebrospinal fluid. Proc. natn. Acad. Sci. U.S.A. 86:1989;6338-6342.
56. Palmert M.R., Podlisny M.B., Golde T.E., Cohen M.L., Kovacs D.M., Tanzi R.E., Gusella J.F., Whitehouse P.J., Witker D.S., Oltersdorf T., et al. The beta amyloid protein precursor: mRNAs, membrane-associated forms, and soluble derivatives. Prog. clin. biol. Res. 317:1989;971-984.
57. Parpura-Gill A., Beitz D., Uemura E. The inhibitory effects of beta-amyloid on glutamate and glucose uptakes by cultured astrocytes. Brain Res. 18:1997;65-71.
58. Piert M., Koeppe R.A., Giordani B., Berent S., Kuhl D.E. Diminished glucose transport and phosphorylation in Alzheimer's disease determined by dynamic FDG-PET. J. nucl. Med. 37:1996;201-208.
59. Qiu W.Q., Walsh D.M., Ye Z., Vekrellis K., Zhang J., Podlisny M.B., Rosner M.R., Safavi A., Hersh L.B., Selkoe D.J. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J. biol. Chem. 273:1998;32,730-32,738.
60. Rapoport S.I. Positron emission tomography in Alzheimer's disease in relation to disease pathogenesis: a critical review. Cerebrovasc. Brain Metab. Rev. 3:1991;297-335.
61. Rapoport S.I., Horwitz B., Grady C.L., Haxby J.V., DeCarli C., Schapiro M.B. Abnormal brain glucose metabolism in Alzheimer's disease, as measured by position emission tomography. Adv. exp. med. Biol. 291:1991;231-248.
62. Saunders A.M., Strittmatter W.J., Schmechel D., St George Hyslop P.H., Pericak-Vance M.A., Joo S.H., Rosi B.L., Gusella J.F., Crapper-MacLachlan D.R., Alberts M.J., Hulette C., Crain B., Goldgaber D. s, Roses A.D. Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 43:1993;1467-1472.
63. Schubert D., LaCorbiere M., Saitoh T., Cole G. Characterization of an amyloid beta precursor protein that binds heparin and contains tyrosine sulfate. Proc. natn. Acad. Sci. U.S.A. 86:1989;2066-2069.
64. Selkoe D. J. (1994) Biochemistry of Alzheimer's disease. In Basic Neurochemistry: Molecular, Cellular and Medical Aspects, 5th edn, pp. 919-933.
65. Shi J., Xiang Y., Simpkins J.W. Hypoglycemia enhances the expression of mRNA encoding beta-amyloid precursor protein in rat primary cortical astroglial cells. Brain Res. 772:1997;247-251.
66. Simmons L.K., May P.C., Tomaselli K.J., Rydel R.E., Fuson K.S., Brigham E.F., Wright S., Lieberburg I., Becker G.W., Brems D.N., et al. Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro. Molec. Pharmac. 45:1994;373-379.
67. Simpson I.A., Chundu K.R., Davies-Hill T., Honer W.G., Davies P. Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease. Ann. Neurol. 35:1994;546-551.
68. Taddei K., Clarnette R., Gandy S.E., Martins R. Increased plasma apolipoprotein E (apoE) levels in Alzheimer's disease. Neurosci. Lett. 223:1997;29-32.
69. Takadera T., Sakura N., Mohri T., Hashimoto T. Toxic effects of a beta-amyloid peptide (beta 22-35) on the hippocampal neuron and its prevention. Neurosci. Lett. 161:1993;41-44.
70. Thome J., Munch G., Muller R., Schinzel R., Kornhuber J., Blum-Degen D., Sitzmann L., Rosler M., Heidland A., Riederer P. Advanced glycation end products-associated parameters in the peripheral blood of patients with Alzheimer's disease. Life Sci. 59:1996;679-685.
71. Wallace W.C., Akakr C.A., Lyons W.E., Kole H.K., Egan J.M., Wolozin B. Amyloid precursor protein requires the insulin signaling pathway for neurotrophic activity. Molec. Brain Res. 52:1997;213-227.
72. Wenham P.R., Price W.H., Blandell G. Apolipoprotein E genotyping by one-stage PCR. [letter]. Lancet. 337:1991;1158-1159.
73. Whyte S., Wilson N., Currie J., Maruff P., Malone V., Shafiq-Antonacci R., Tyler P., Derry K.L., Underwood J., Li Q.X., Beyreuther K., Masters C.L. Collection and normal levels of the amyloid precursor protein in plasma. Ann. Neurol. 41:1997;121-124.
74. Yang D., Smith J.D., Zhou Z., Gandy S.E., Martins R.N. Characterization of the binding of amyloid-ß peptide to cell culture-derived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma. J. Neurochem. 68:1997;721-725.
75. Yankner B., Dawes L., Fisher S., Villa-Konaroff L., Oster-Granite M., Neve R. Neurotoxicity of a fragment of the amyloid precorsor associated with Alzheimer's disease. Science. 245:1989;417-420.
76. Yasuno F., Imamura T., Hirono N., Ishii K., Sasaki M., Ikejiri Y., Hashimoto M., Shimomura T., Yamashita H., Mori E. Age at onset and regional cerebral glucose metabolism in Alzheimer's disease. Dement. geriatr. cogn. Disord. 9:1998;63-67.
77. Zhao X.H., Schoenheit C., Duffy L.K. A heparin-binding protein from neuroblastoma cells: immunological comparison to beta-amyloid precursor protein. Comp. Biochem. Physiol. 100:1991;715-718.